Circulating Extracellular Matrix Products as Indicators of Disease Burden and Predictors of Disease Course in Ulcerative Colitis
Authors:
- Anja PoulsenAPAnja Poulsen
- Marta Sorokina AlexdóttirMAMarta Sorokina Alexdóttir
- Lene Buhl RiisLRLene Buhl Riis
- Martin PehrssonMPMartin Pehrsson
- Lars Tue SørensenLSLars Tue Sørensen
- Peter-Martin KrarupPKPeter-Martin Krarup
- Anne-Christine Bay-JensenABAnne-Christine Bay-Jensen
- Morten A KarsdalMKMorten A Karsdal
- Ryan W StidhamRSRyan W Stidham
- Johan BurischJBJohan Burisch
- Joachim Høg MortensenJMJoachim Høg Mortensen
- Jakob Benedict SeidelinJSJakob Benedict Seidelin
- 22 October 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (3) , 751-762
Abstract
Background: Ulcerative colitis (UC) is characterized by recurrent inflammation and challenging disease monitoring, with invasive endoscopy as the primary diagnostic tool despite the inadequacy of standard noninvasive biomarkers. This study evaluates serum extracellular matrix (ECM) fragments, which reflect the remodeling of mucosa and submucosa, as potential indicators of disease burden and treatment efficacy. We aim to determine whether serum ECM levels correlate with the extent and severity and predict treatment response. Methods: We conducted a prospective study comparing serum ECM formation (PRO-C3, PRO-C7, PRO-C11, PRO-C22), turnover (PRO-C4), and degradation markers (C1M, C3M, C4M, C7M) at Weeks 0, 12, and 24 in 49 UC patients and 50 healthy controls measured by enzyme-linked immunosorbent assay. Results: ECM biomarkers, notably PRO-C11, differentiated UC patients from controls (area under the curve [AUC] 0.77), and PRO-C3 predicted endoscopic treatment response vs nonresponse (AUC 0.74). C7M separated moderate from severe disease in endoscopy (AUC 0.74) as well as mild from severe disease (AUC 0.84), as did the ratio C7M/PRO-C7 (AUC 0.82). Combining new and conventional markers, including hemoglobin, C-reactive protein, PRO-C3, and PRO-C22, achieved a combined AUC of 0.84 for predicting 24-week endoscopic response, adding index endoscopic activity increased the AUC to 0.92 compared to an AUC of 0.84 for endoscopy alone. Conclusions: Soluble ECM fragments reflect endoscopic disease severity and extent and are also predictive of therapeutic efficacy. They may as well reflect degenerative aspects of UC and may as such be future therapeutic targets aimed at prevention of intestinal damage.Keywords
Funding Information
- Overlæge Poul Martin Christiansen og Hustrus Foundation
- Grosserer L. F. Foghts Foundation
- Aase og Ejnar Danielsens Foundation (20-10-0344)
This publication has 45 references indexed in Scilit:
- AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Ulcerative ColitisGastroenterology, 2023
- Noninvasive prognostic biomarker potential of quantifying the propeptides of Type XI collagen alpha‐1 chain (PRO‐C11) in patients with pancreatic ductal adenocarcinomaInternational Journal of Cancer, 2021
- Comprehensive assessment of ECM turnover using serum biomarkers establishes PBC as a high-turnover autoimmune liver diseaseJHEP Reports, 2021
- Patient-Reported Outcome Measures for Use in Clinical Trials and Clinical Practice in Inflammatory Bowel Diseases: A Systematic ReviewClinical Gastroenterology and Hepatology, 2018
- De Novo Anti-Type VII Collagen Antibodies in Patients with Recessive Dystrophic Epidermolysis BullosaJournal of Investigative Dermatology, 2014
- Reliability and Initial Validation of the Ulcerative Colitis Endoscopic Index of SeverityGastroenterology, 2013
- A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagenClinical Biochemistry, 2010
- Collagens—structure, function, and biosynthesisAdvanced Drug Delivery Reviews, 2003
- The Epidermolysis Bullosa Acquisita Antigen (Type VII Collagen) is Present in Human Colon and Patients with Crohn's Disease have Autoantibodies to Type VII CollagenJournal of Investigative Dermatology, 2002
- Skeletal muscle injury—molecular changes in the collagen during healingZeitschrift für Die Gesamte Experimentelle Medizin, 1985